Applied DNA Sciences Inc. (NASDAQ:APDN) Q2 2020 Earnings Conference Call - Final Transcript
May 14, 2020 • 04:30 pm ET
Technology Program that creates a pathway for us to DNA tag pharmaceuticals and packaging. The ETP serves to help promote the adoption of innovative approaches to pharmaceutical product design and manufacturing, and offers technology companies and their pharmaceutical customers the opportunity to discuss, identify and resolve potential technical and regulatory pathways early in the development and implementation of a novel technology like ours.
Our inclusion in the ETP, we believe, should make for a smoother regulatory path for pharmaceutical customers who seek to employ the DNA marking of their pharmaceutical products in order to forensically prove their authenticity or their point of origin. The interest of the FDA in our tagging platform, we expect, will help us to recruit manufacturers of drugs whose patients want to ensure their supply chains are intact. It is not hard to imagine the positive impact we might still have on the opioid crisis or the transformation to come in global supply chains.
So now in conclusion, looking ahead to the second half of our fiscal year, we're primarily focused on our COVID-19 developments and, more broadly, our biopharma opportunity. With our EUA in hand, we're focused on commercializing our diagnostic kit, which we strongly believe, given its relative advantages in the market, can help all of us mitigate infection rates. We will stay the course of our therapeutic applications of linear DNA, especially our promising vaccines with Takis, our CAR T therapy and our CRO to CMO business.
Now as Beth stated, our cash position gives us a cushion with which to pursue our near-term objectives. We are also very grateful to receive funds under the Paycheck Protection Program, so we can continue to pursue our vital work with the full application of Applied DNA personnel.
Well, thank you for your time and attention this afternoon. This concludes my prepared remarks. Operator, can you please open the call to questions.